hemagel animace
hemagel procto
jak HemaGel funguje
chronické rány
akutní rány
fotogalerie
poradna HemaGelu - položit dotaz
poradna HemaGelu - časté dotazy

The road to patent acquisition


Work and research that led to the development of the medical agent offered today under the commercial name HemaGel began in the first half of the 1990s.The research begun then would not have been possible though without the previous results of the Institute of Macromolecular Chemistry of the Academy of Sciences of the Czech Republic. Even HemaGel in a way owes its existence to the discovery and development of hydrophilic polymers based on poly (2-hydroxyethyl methacrylate). The discovery made by Prof. Wichterle and his team, which in the 1960s enabled the launch of soft contact lenses, thus forms the basis of HemaGel.

The research team witnessed an important breakthrough in the mid 1990s, when it was possible to implement the idea of Eng. Jiří Labský, CSc. on the fitting of sterically shielded amines , so-called “free radical scavengers”, into certain polymers well-tolerated by the human organism. Free radicals that form in massive amounts every time tissue is damaged react with these amines (or rather with their oxidative derivates). The resulting reaction neutralises these free radicals and thus prevents their otherwise aggressive actions on the organism.

The polymer matrix used has several advantages. It consists of large macromolecules mutually interconnected to form a network. This prevents the penetration of these molecules through the skin into the body and they thus remain on the surface of the wound. This allows the continued activity of the substance.

In 1997, the project was awarded a Czech patent. Nonetheless, the road towards a freely accessible agent was not over yet. Transformation of results acquired in the laboratory into an operational form enabling large volume production was very complicated. The team had to resolve many questions relating to the optimisation of its composition. The issues and obstacles involved demanded that equilibrium between product efficacy and price be found in order for industrial production to begin.

The Institute of Macromolecular Chemistry of the Academy of Sciences of the Czech Republic holds the patent and is contractually bound to provide the production rights to the agent (commercially known as HemaGel) to Wake Ltd. TEAM 4 YOU Ltd. holds the exclusive commercial and marketing representation rights.

Launch of the hydrophilic gel HemaGel on the market did not bring the whole research project to a close. Research and development continue. The working team of Eng. Zdeňka Sedlkovå CSc is now studying the possibilities of further increasing efficacy and it is also testing alternative forms of application.

The patent creators

Ing. Jiří Labský, CSc. (* 1936)
is the author of more than 100 publications in international journals and of 55 patents. In 2002, he was awarded together with Karel Smetana MD,, DrSc. the prestigious Czech Brain award. His theory of fitting sterically shielded amines , so-called “free radical scavengers”, into certain polymers well-tolerated by the human organism was fundamental for the development of HemaGel. He also discovered possible means of implementing this theory.

Ing. Jiří Vacík, CSc. (* 1938)
was the Head of the Department of Hydrogels for Medical and Technical Practice of the Institute of Macromolecular Chemistry of the Academy of Sciences of the Czech Republic in the 1990s and he headed the team working on the development of HemaGel. Over more than 40 years of scientific activities at the Institute, he published 58 expert articles and he is the author of 47 patent applications.

Pavel HoĹĄek MD (* 1948)
worked as a general practitioner. During the research, he was principally involved in the practical testing of the gel.
THE DEVELOPMENT

The exceptional medical device Hemagel owes its unique structure and efficacy to the scientists from Institute of Macromolecular Chemistry.

Cesta k získání patentu
Makromolekulární ústav AV ČR
CLINICAL STUDIES

The results of clinical tests and studies have confirmed that HemaGel is a highly effective hydrophilic gel patch suitable for a wide range of skin wounds.

Nejvýznamnější klinické studie
Applying HemaGel

As HemaGel may be used to treat a wide range of wounds that vary in their extent, severity and causes, the correct application of HemaGel or frequency of dressing changes may differ.

Návody na ošetření chronických ran
Návody na ošetření akutních ran
NEW HemaGel Procto

HemaGel PROCTO suppositories are used as a supportive treatment of haemorrhoids and other rectal diseases such as painful skin cracks (anal fissures) and tears in the anal skin and mucosa (anal rhagades).

HemaGel PROCTO
Copyright 2011 TEAM 4 YOUŽ spol. s r.o.

english version slovenian version greek version